Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

US Food and Drug Administration Approval of New Drugs Based on Noninferiority Trials in Oncology

US Food and Drug Administration Approval of New Drugs Based on Noninferiority Trials in Oncology This Viewpoint highlights the drawbacks of US Food and Drug Administration approval of lenvatinib for unresectable hepatocellular cancer based on the results of a noninferiority trial. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

US Food and Drug Administration Approval of New Drugs Based on Noninferiority Trials in Oncology

JAMA Oncology , Volume 5 (5) – May 28, 2019

Loading next page...
 
/lp/american-medical-association/us-food-and-drug-administration-approval-of-new-drugs-based-on-jogSRuAu0L
Publisher
American Medical Association
Copyright
Copyright 2019 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2019.0093
Publisher site
See Article on Publisher Site

Abstract

This Viewpoint highlights the drawbacks of US Food and Drug Administration approval of lenvatinib for unresectable hepatocellular cancer based on the results of a noninferiority trial.

Journal

JAMA OncologyAmerican Medical Association

Published: May 28, 2019

References